Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts

• US 7,780,993 B2
• Filed: 01/19/2005
• Issued: 08/24/2010
• Est. Priority Date: 09/07/2001
• Status: Expired due to Fees

• Current Assignee: Yeda Research and Development Co. Ltd. (Weizmann Institute of Science)
• Original Assignee: Yeda Research and Development Co. Ltd. (Weizmann Institute of Science)
• Inventors: Aronovich, Anna, Reisner, Yair, Tchorsh, Dalit, Katchman, Helena, Shezen, Elias, Dekel, Benjamin, Eventov-Friedman, Smadar
• Primary Examiner(s): Kim; Taeyoon
• Application Number:
  US11/037,025
• Publication Number:
  US 20050226854A1
• Time in Patent Office: 2,043 Days
• Field of Search: None
• US Class Current: 424/582
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/22 Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
• CPC Class Codes: A61K 35/407 Liver; Hepatocytes
• CPC Class Codes: A61K 35/54 Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
• CPC Class Codes: A61K 39/39541 against normal tissues, cells
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61L 2430/28 for liver reconstruction
• CPC Class Codes: A61L 27/3604 characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
• CPC Class Codes: A61L 27/3641 characterised by the site of application in the body materials for artificial blood vessels A61L27/507; materials for use in artificial skin A61L27/60
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

A method of treating a renal, hepatic or enzyme-deficiency disorder in a subject in need thereof is disclosed. The method is effected by transplanting into the subject tissue derived from a human or porcine, kidney or liver, the kidney or liver being at a selected gestational stage.

Claims

1. A method of alleviating or stabilizing a hepatic, or hepatic enzyme-deficiency disorder in a subject in need thereof, the method comprising transplanting hepatic organ precursor/tissue into the subject, said hepatic organ precursor/tissue being derived from a porcine liver being at a stage of development of 28 days of gestation.

2. The method of claim 1, further comprising treating the subject with an immunosuppressive regimen prior to, concomitantly with or following said transplanting said hepatic organ precursor/tissue into the subject, thereby promoting engraftment of said organ precursor/tissue in the subject.

3. The method of claim 2, wherein said treating the subject with an immunosuppressive regimen is effected by administering at least one immunosuppressant drug to the subject.

4. The method of claim 3, wherein said at least one immunosuppressant drug is capable of blocking binding of a lymphocyte coreceptor with a ligand of said lymphocyte coreceptor.

5. The method of claim 4, wherein said at least one immunosuppressant drug is capable of blocking binding of a lymphocyte coreceptor with a ligand of said lymphocyte coreceptor, and wherein said administering said at least one immunosuppressant drug to the subject is effected during a time period selected from a range of 1 to 60 days.

6. The method of claim 4, wherein said lymphocyte coreceptor is selected from the group consisting of CD28 and CD40.

7. The method of claim 4, wherein said ligand of said lymphocyte coreceptor is selected from the group consisting of B7-1 and CD40L.

8. The method of claim 3, wherein said at least one immunosuppressant drug comprises CTLA4-Ig.

9. The method of claim 3, wherein said at least one immunosuppressant drug comprises CTLA4-Ig and anti-CD40L antibody.

10. The method of claim 3, wherein said at least one immunosuppressant drug comprises CTLA4-Ig, anti-CD40L antibody and rapamycin.

11. The method of claim 1, wherein said transplanting said hepatic organ precursor/tissue into the subject is effected by transplanting said hepatic organ precursor/tissue into an anatomical location of the subject selected from the group consisting of the portal vein, the liver, the renal capsule, the sub-cutis, the omentum, the spleen, and the intra-abdominal space.

12. The method of claim 1, wherein the subject is a mammal.

13. The method of claim 1, wherein said porcine liver is non-syngeneic with the subject.

14. The method of claim 1, wherein said porcine liver is xenogeneic with the subject.

29. The method of claim 1, wherein said subject is a human subject.

15. A method of alleviating or stabilizing a hepatic, or hepatic enzyme-deficiency disorder in a subject in need thereof, the method comprising transplanting non-cultured hepatic organ precursor/tissue into the subject, said non-cultured hepatic organ precursor/tissue being derived from a porcine liver being at a stage of development of 28 days of gestation.

16. The method of claim 15, further comprising treating the subject with an immunosuppressive regimen prior to, concomitantly with or following said transplanting said non-cultured hepatic organ precursor/tissue into the subject, thereby promoting engraftment of said organ precursor/tissue in the subject.

17. The method of claim 16, wherein said treating the subject with an immunosuppressive regimen is effected by administering at least one immunosuppressant drug to the subject.

18. The method of claim 17, wherein said at least one immunosuppressant drug is capable of blocking binding of a lymphocyte coreceptor with a ligand of said lymphocyte coreceptor.

19. The method of claim 18, wherein said at least one immunosuppressant drug is capable of blocking binding of a lymphocyte coreceptor with a ligand of said lymphocyte coreceptor, and wherein said administering said at least one immunosuppressant drug to the subject is effected during a time period selected from a range of 1 to 60 days.

20. The method of claim 18, wherein said lymphocyte coreceptor is selected from the group consisting of CD28 and CD40.

21. The method of claim 18, wherein said ligand of said lymphocyte coreceptor is selected from the group consisting of B7-1 and CD40L.

22. The method of claim 17, wherein said at least one immunosuppressant drug comprises CTLA4-Ig.

23. The method of claim 17, wherein said at least one immunosuppressant drug comprises CTLA4-Ig and anti-CD40L antibody.

24. The method of claim 17, wherein said at least one immunosuppressant drug comprises CTLA4-Ig, anti-CD40L antibody and rapamycin.

25. The method of claim 15, wherein said transplanting said non-cultured hepatic organ precursor/tissue into the subject is effected by transplanting said non-cultured hepatic organ precursor/tissue into an anatomical location of the subject selected from the group consisting of the portal vein, the liver, the renal capsule, the sub-cutis, the omentum, the spleen, and the intra-abdominal space.

26. The method of claim 15, wherein the subject is a mammal.

27. The method of claim 15, wherein said porcine liver is non-syngeneic with the subject.

28. The method of claim 15, wherein said porcine liver is xenogeneic with the subject.

30. The method of claim 15, wherein said subject is a human subject.